DOUBEK, Michael, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, J. TRIZULJAK, Ludmila ŠEBEJOVÁ, Olga STEHLÍKOVÁ, Jana CHOVANCOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Karla PLEVOVÁ, Pavlína VOLFOVÁ, Martin TRBUŠEK, Marek MRÁZ, Denisa MAJERČÁKOVÁ, Petra OBRTLÍKOVÁ, Josef KARBAN, Lukáš SMOLEJ, Michaela LINDTNEROVÁ, Alexandra OLTOVÁ, Eva JELÍNKOVÁ, Šárka POSPÍŠILOVÁ and Jiří MAYER. Ofatumumab added to dexamethasone in patients with relapsed of refractory chronic lymphocytc leukemia. Results from a phase II study of the czech leukemia study group for life. In 55th ASH Annual Meeting and Exposition. 2013.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Ofatumumab added to dexamethasone in patients with relapsed of refractory chronic lymphocytc leukemia. Results from a phase II study of the czech leukemia study group for life
Authors DOUBEK, Michael, Yvona BRYCHTOVÁ, Anna PANOVSKÁ, J. TRIZULJAK, Ludmila ŠEBEJOVÁ, Olga STEHLÍKOVÁ, Jana CHOVANCOVÁ, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Karla PLEVOVÁ, Pavlína VOLFOVÁ, Martin TRBUŠEK, Marek MRÁZ, Denisa MAJERČÁKOVÁ, Petra OBRTLÍKOVÁ, Josef KARBAN, Lukáš SMOLEJ, Michaela LINDTNEROVÁ, Alexandra OLTOVÁ, Eva JELÍNKOVÁ, Šárka POSPÍŠILOVÁ and Jiří MAYER.
Edition 55th ASH Annual Meeting and Exposition, 2013.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Organization unit Central European Institute of Technology
Tags International impact, Reviewed
Changed by Changed by: Bc. Kateřina Kolesová, učo 112275. Changed: 3/1/2014 10:54.
PrintDisplayed: 19/7/2024 01:33